Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma.
Park DY, Tom MC, Wei W, Tewari S, Ahluwalia MS, Yu JS, Chao ST, Suh JH, Peereboom D, Stevens GHJ, Barnett GH, Angelov L, Mohammadi AM, Hogan T, Kissel C, Lapin B, Schuermeyer I, Parsons MW, Naugle R, Murphy ES.
Park DY, et al. Among authors: murphy es.
J Neurooncol. 2022 Feb;156(3):499-507. doi: 10.1007/s11060-021-03920-6. Epub 2022 Jan 22.
J Neurooncol. 2022.
PMID: 35064450
No significant decline was seen in EQ-5D or PHQ-9 scores at 3, 6, 9, 12, and 24 months compared to baseline scores for all patients. ...The linear mixed model estimating PHQ-9 value or EQ-5D index demonstrated that there was no significant difference in PHQ-9 or EQ- …
No significant decline was seen in EQ-5D or PHQ-9 scores at 3, 6, 9, 12, and 24 months compared to baseline scores for all patients. …